Relevant bibliographies by topics / Antianginal agent

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters

Academic literature on the topic 'Antianginal agent'

Author: Grafiati
Published: 4 June 2021
Last updated: 9 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antianginal agent.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antianginal agent"

1

Zeller, Frederick P., and Sarah A. Spinier. "Bepridil: A New Long-Acting Calcium Channel Blocking Agent." Drug Intelligence & Clinical Pharmacy 21, no. 6 (1987): 487–92. http://dx.doi.org/10.1177/106002808702100601.

Full text
Abstract:
Bepridil is an investigational calcium channel blocking agent with antianginal activity that has a distinct and complex pharmacologic profile. Bepridil produces significant coronary vasodilation and modest peripheral effects, in addition to negative inotropic and chronotropic effects. Bepridil favorably modifies both myocardial oxygen demand and supply, supporting its use as an antianginal drug. Electrophysiologically, bepridil exhibits classes I, III, and IV antiarrhythmic activity. Five U.S. trials evaluating the short-term antianginal efficacy of bepridil collectively reported that bepridil
APA, Harvard, Vancouver, ISO, and other styles
2

Maqueda, I. González. "Treatment of Chronic Stable Angina with Carvedilol: A Multiple-Action Neurohormonal Antagonist. A Review of Controlled Clinical Trials." Journal of International Medical Research 26, no. 3 (1998): 107–19. http://dx.doi.org/10.1177/030006059802600301.

Full text
Abstract:
Beta-blockers and vasodilators, such as nitrates and calcium channel blockers, are all established antianginal therapies. These therapies have different antianginal mechanisms that dictate both their mode of action and their side-effect profile. An agent with both cardiac beta- and vascular alpha-receptor activity offers advantages over these conventional drugs. Carvedilol, a multiple-action neurohormonal antagonist, has potent antihypertensive and antianginal activity. Through its combination of pharmacological mechanisms, it reduces myocardial oxygen demand, increases myocardial blood supply
APA, Harvard, Vancouver, ISO, and other styles
3

Lazar, Eliot J., and William H. Frishman. "Profile of an Ideal Antianginal Agent." Drugs 38, Supplement 2 (1989): 1–8. http://dx.doi.org/10.2165/00003495-198900382-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Aalla, Sampath, Goverdhan Gilla, Raghupathi Reddy Anumula, Srinivas Kurella, Pratap Reddy Padi, and Prabhakar Reddy Vummenthala. "Improved Process for Ranolazine: An Antianginal Agent." Organic Process Research & Development 16, no. 5 (2012): 748–54. http://dx.doi.org/10.1021/op300026r.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Planellas, J., Ph Coudray, E. Winslow, and R. Massingham. "Dopropidil, A Novel Antianginal Calcium Modulating Agent." Cardiovascular Drug Reviews 12, no. 3 (1994): 208–24. http://dx.doi.org/10.1111/j.1527-3466.1994.tb00206.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vadnais, David S., and Nanette K. Wenger. "Management Options in Chronic Stable Angina Pectoris: Focus on Ranolazine." Clinical Medicine. Therapeutics 1 (January 2009): CMT.S2214. http://dx.doi.org/10.4137/cmt.s2214.

Full text
Abstract:
Chronic stable angina pectoris results from a fixed coronary arterial obstruction causing an imbalance between myocardial oxygen supply and demand. Current therapy aims to reduce cardiovascular events (vasculoprotective) thereby improving survival, and/or relieve ischemic symptoms (antianginal) thereby improving the quality of life. Vasculoprotective therapy consists of lifestyle modification, antiplatelet agents, lipid lowering therapy and angiotensin-converting enzyme (ACE) inhibitors. Conventional antianginal therapy for patients with chronic stable angina consists of beta-blockers, calcium
APA, Harvard, Vancouver, ISO, and other styles
7

Jaraki, Omar, William E. Strauss, Stephanie Francis, Joseph Loscalzo, and Jonathan S. Stamler. "Antiplatelet Effects of a Novel Antianginal Agent, Nicorandil." Journal of Cardiovascular Pharmacology 23, no. 1 (1994): 24–56. http://dx.doi.org/10.1097/00005344-199401000-00024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Udeoji, Dioma U., and Ernst R. Schwarz. "Switching from Nitrate Therapy to Ranolazine in Patients with Coronary Artery Disease Receiving Phosphodiesterase Type-5 Inhibitors for Erectile Dysfunction." Clinical Medicine Insights: Case Reports 7 (January 2014): CCRep.S16915. http://dx.doi.org/10.4137/ccrep.s16915.

Full text
Abstract:
Coronary artery disease (CAD) and erectile dysfunction (ED) frequently coexist. The introduction of phosphodiesterase type-5 (PDE-5) inhibitors has revolutionized medical management of organic ED; however, in patients with angina pectoris, a common symptom of CAD, coadministration of PDE-5 inhibitors and nitrates has been implicated in CAD-related deaths following sexual activity. The mechanism of action of PDE-5 inhibitors results in a potential cumulative drop in blood pressure (BP); thus, these agents are contraindicated in patients receiving nitrates. Beta-blockers and calcium channel anta
APA, Harvard, Vancouver, ISO, and other styles
9

SAKAI, Kazushige, Tamotsu YAMAZAKI, Yasuyuki NAKAMURA, and SUGIMOTO Tetsuro. "Protective Effects of the Antianginal Agent Nicorandil on Arachidonate-lnduced Sudden Death in Rats: Comparison with Several Antianginal Agents and Cyclooxygenase Inhibitors." Japanese Journal of Pharmacology 37, no. 1 (1985): 124–28. http://dx.doi.org/10.1254/jjp.37.124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

ter Wee, P. M., T. K. Kremer Hovinga, D. R. A. Uges, and S. van der Geest. "4-Aminopyridine and Haemodialysis in the Treatment of Verapamil Intoxication." Human Toxicology 4, no. 3 (1985): 327–29. http://dx.doi.org/10.1177/096032718500400315.

Full text
Abstract:
Verapamil, a calcium antagonist, is used as an antianginal, antidysrhythmic and antihypertensive agent. Fatal intoxications with this commonly used drug have been described. We report the effects of 4-aminopyridine and haemodialysis in a patient with severe verapamil intoxication.
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Antianginal agent"

1

Marciniak, Gilbert. "Nouveaux heterocycles doues d'activites antiangineuses, inotropes positives ou antagonistes des canaux calciques : synthese, modelisation et relations structure-activite." Université Louis Pasteur (Strasbourg) (1971-2008), 1987. http://www.theses.fr/1987STR13142.

Full text
Abstract:
Recherche par modelisation moleculaire sur ordinateur d'une structure commune a cinq inotrpes positifs connus ; synthese et proprietes pharmacologiques de nouveaux inotropes positifs (pyridyl-quinoles) ; preparation et pharmacologie de composes apparentes a la perhexiline ; synthese et activite biologique de dihydropyridines
APA, Harvard, Vancouver, ISO, and other styles
2

Leboeuf, Jackie. "Effets du bepridil sur les proprietes electrophysiologiques et contractiles du muscle cardiaque : mise en evidence d'une action intracellulaire." Nantes, 1987. http://www.theses.fr/1987NANT2001.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Antianginal agent"

1

U, Abshagen, ed. Clinical pharmacology of antianginal drugs. Springer-Verlag, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Charlier, Robert. Antianginal Drugs: Pathophysiological, Haemodynamic, Methodological, Pharmacological, Biochemical and Clinical Basis for Their Use in Human Therapeutics. Brand: Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Charlier, Robert. Antianginal Drugs: Pathophysiological, Haemodynamic, Methodological, Pharmacological, Biochemical and Clinical Basis for Their Use in Human Therapeutics. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Antianginal agent"

1

Nayler, Winifred G. "Amlodipine and the Coronary Circulation: Is it a Useful Antianginal Agent?" In Amlodipine. Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-78223-7_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pitschner, H. F., E. Muno, F. Vens-Cappel, et al. "Antiischemic, antianginal, and hemodynamic effects of ULFS 49 CL (a new heart-rate-reducing agent) in patients with angiographically proven CAD." In Sinus node inhibitors. Steinkopff, 1991. http://dx.doi.org/10.1007/978-3-642-72458-9_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Thadani, Udho. "Dose-Response Relationships and Combination Studies with Antianginal Agents." In Developments in Cardiovascular Medicine. Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-2628-5_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Opie, Lionel H. "Efficacy and Safety of Calcium Antagonists as Antianginal Agents." In Developments in Cardiovascular Medicine. Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-2628-5_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Motolese, Mario. "Controlling Potential Sources of Bias in Clinical Trials of Antianginal Agents." In Developments in Cardiovascular Medicine. Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-2628-5_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Stauch, M. "Therapy of coronary heart disease with nitrates in combination with other antianginal agents." In Nitroglycerin 5, edited by Bodo E. Strauer. De Gruyter, 1987. http://dx.doi.org/10.1515/9783110898262-010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fleckenstein, A., and G. Fleckenstein-Grün. "Effects of and the Mechanism of Action of Calcium Antagonists and Other Antianginal Agents." In Physiology and Pathophysiology of the Heart. Springer US, 1989. http://dx.doi.org/10.1007/978-1-4613-0873-7_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mohanty, Ipseeta. "Antianginal Agents." In Drug Screening Methods. Jaypee Brothers Medical Publishers (P) Ltd., 2016. http://dx.doi.org/10.5005/jp/books/12723_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Waldmann, Carl, Andrew Rhodes, Neil Soni, and Jonathan Handy. "Cardiovascular drugs." In Oxford Desk Reference: Critical Care. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198723561.003.0012.

Full text
Abstract:
Haemodynamic instability is one of the main reasons for admission to critical care. Often patients will require medication to provide cardiovascular support. This chapter discusses cardiovascular drugs and includes discussion on β‎-adrenergic agonists, phosphodiesterase inhibitors, vasodilators, vasopressors, antiarrhythmics in intensive care, chronotropes, antianginal agents, antiplatelet agents, diuretics and the critically ill, and levosimendan. These medications are part of the daily practise in intensive care. Knowledge of the indications, interactions, and adverse effects is essential.
APA, Harvard, Vancouver, ISO, and other styles
10

Laurent, Stéphane. "Pharmacology of vasodilators." In ESC CardioMed. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0034.

Full text
Abstract:
Antihypertensive and antianginal agents are differentially able to vasodilate small resistance arteries, large conducting arteries, and epicardial coronary arteries. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and alpha-adrenergic antagonists are not addressed here, since they are discussed in specific chapters. This chapter discusses the pharmacology of calcium channel blockers, nitrovasodilators, and direct-acting vasodilators. Dihydropyridines, such as nifedipine and amlodipine, are compared to the non-dihydropyridine agents verapamil and diltiazem. Organic nitrates, such as nitroglycerine and isosorbide dinitrate, are compared to inorganic nitrates, such as sodium nitroprusside. Molsidomine and nicorandil are also discussed. Finally, the pharmacology of direct-acting vasodilators focuses on minoxidil and hydralazine. Pharmacology of mechanisms of action is detailed to better understand therapeutic indications and side effects.
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography